
INBX Stock Forecast & Price Target
INBX Analyst Ratings
Bulls say
Inhibrx Biosciences Inc is positioned favorably with $186.6 million in cash, providing substantial capital for the continued development of its key therapeutic candidates, INBRX-109 and INBRX-106, with critical readouts anticipated in the fourth quarter of 2025. The company’s proprietary single-domain antibody and protein engineering platforms present long-term value potential, enhancing the attractiveness of its innovative drug pipeline. Additionally, Inhibrx generated revenue of $1.3 million in the second quarter of 2025 from a license agreement with Regeneron Pharmaceuticals, indicating ongoing commercial collaboration and financial stability.
Bears say
Inhibrx Biosciences faces a negative outlook primarily due to the potential for stock price declines even if the company meets investor expectations, indicating underlying market concerns beyond performance metrics. Additionally, the risk of failure to achieve regulatory approval or experiencing delays in approval timelines poses a significant threat to the company's share price, highlighting uncertainty in the approval landscape for its clinical candidates. Furthermore, the variance in Research and Development expenses, reported at $22.3 million compared to the estimated $36.9 million, raises concerns about the adequacy of investment in key developmental areas, potentially jeopardizing future product initiatives and growth.
This aggregate rating is based on analysts' research of Inhibrx Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
INBX Analyst Forecast & Price Prediction
Start investing in INBX
Order type
Buy in
Order amount
Est. shares
0 shares